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 Abstract
When designing molecular targeted therapeutic strategies against cancer, it is important
to correlate protein expression and cell viability. However, such goal can be difficult if
performed in separate assays, especially when only a fraction of cells has been efficiently
transfected. Therefore, the aim of the present study was to establish a flow cytometry
procedure to assess simultaneously Bcl-2 protein level and viability in small-cell lung
cancer (SCLC) cells. Viability assessment was performed by staining cells with Annexin
V-fluorescein isothiocyanate (FITC) and 7-aminoactinomycin D (7-AAD). Intracellular
detection of Bcl-2 was carried out by immunodetection with monoclonal antibodies.
Regarding viability determination, the FSC/7-AAD plot identifies the same percentage
of viable cells as the FSC/Annexin V-FITC plot, although with greater sensitivity. The
procedures involving cells’ fixation with 1% paraformaldehyde and permeabilization
with digitonin, required for intracellular Bcl-2 immunostaining did not compromise
the association of 7-ADD (nor Annexin V-FITC) previously incubated with SCLC cells.
It was therefore possible to simultaneously assess cell viability and Bcl-2 protein in
SCLC cells. A simple, sensitive, and versatile procedure was established for the first time
for the simultaneous evaluation of cell viability and intracellular detection of Bcl-2 in
SCLC. ' 2008 International Society for Advancement of Cytometry
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ELUCIDATION of the human genome has provided a major impetus in identifying
human genes implicated in diseases, namely within cancer, leading to the develop-
ment of novel classes of pharmaceutical drugs, aiming at achieving higher specificity
and potency of action than conventional anticancer agents. Gene silencing agents
(such as antisense oligonucleotides, ODN, or siRNA) are one example of a novel class
of drugs that have shown efficacy in the selective inhibition of gene expression by
inhibiting the translation of the mRNA of the target gene (1–3). When designing a
therapeutic anticancer strategy, tumor cell death is the major ultimate goal. In this
context, the establishment of correlations between protein expression and viability
are important, but can be difficult, namely if performed in separate assays. Parame-
ters like the percentage of cells effectively transfected (4), the occurrence of unspecific
effects as a consequence of the transfection procedure, the possibility of distinct dif-
ferentiation states, or the regulation of protein expression and/or protein function
along the cell cycle, can make the cell populations in study extremely heterogeneous.
Real time PCR, Western blot, and cytotoxicity assays such as the MTT assay, are often
used to evaluate the impact of a gene silencing strategy on the mRNA level, protein
expression or cell viability, respectively (5,6). Nevertheless, it is important to point
out that the outcome of the mentioned techniques represents the summation of the
effects within the entire cell population. A true understanding of the impact of mo-
lecular targeted strategies, as gene silencing, against diseases like cancer, demands the
establishment of procedures that evaluate protein expression within several sub-
populations of a certain tumor type.
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Flow cytometry, whenever applicable, provides important
insights on the relation between the levels of protein expres-
sion and its function, by granting the possibility to study
several cell parameters at the same time, and to study hetero-
geneous cell populations with respect to each identifiable sub-
population. The technique has been extensively used in the
field of hematology, either in the clinical or in the fundamen-
tal research contexts. However, when adapting the procedures
to different applications, a careful evaluation of their suitabil-
ity to the cells in study is required. Previous examples have
proven this necessity, such as the one involving peripheral
blood mononuclear cells (PBMC) from AIDS patients, where
methods usually applied to the study of apoptosis in PBMC
from healthy donors were discordant among themselves or
simply inappropriate (7,8).
The BCL2 gene is frequently overexpressed in SCLC (9–
14), and has been proposed as a proto-oncogene with rele-
vance for the survival of these cells (15). SCLC cell lines are in
their majority suspension cells, and are characteristically diffi-
cult to transfect (authors’ unpublished observations). The
study of Bcl-2 silencing approaches in these cells, namely on
their viability, would therefore benefit from a simple method
like flow cytometry, capable of discriminating the Bcl-2 level
at the single cell level and the viability outcome of the effec-
tively transfected cells. Assessment of viability can be per-
formed, for example, with Annexin Vor 7-AAD. Double stain-
ing with fluorescently labeled Annexin V and propidium
iodide (PI) or 7-AAD has been extensively used to detect and
quantify apoptosis induction, although it should not be used
to characterize the mechanism of cell death because it also
stains oncotic cells (16). From previous reports, Annexin V
staining is expected to be compatible with cell fixation (8) and
cell permeabilization (17); however, there are no reports, to
the authors’ knowledge, of any procedure of staining cells con-
comitantly with Annexin V and an antibody against an intra-
cellular protein. The usefulness of 7-AAD alone to stain non-
viable cells or to distinguish early apoptotic cells from viable
and late apoptotic/necrotic cells, upon analysis in combination
with the forward side scatter (FSC) parameter, has been also
reported (18). However, concomitant cell staining with 7-
AAD for viability assessment and Bcl-2 immunodetection
with anti-Bcl-2 antibodies has also never been reported in
SCLC.
The main goal of the present study was to establish a flow
cytometry procedure to assess simultaneously Bcl-2 protein
level and viability in SCLC cells. Moreover, a comparison
between different viability markers (Annexin V-FITC versus
7-AAD) for SCLC cells was also performed.
MATERIALS AND METHODS
Materials
All salts and paraformaldehyde (PFA) were from Merck
(Darmstadt, Germany). 4-(2-hydroxyethyl)-1-piperazine-eth-
anesulfonic acid (HEPES), 2-amino-2-(hydroxymethyl)pro-
pane-1,3-diol (Tris), sodium azide (N3Na), actinomycin D
(AD), 7-AAD, bovine serum albumin (BSA), RPMI 1640 with
L-glutamine and without sodium bicarbonate (RPMI 1640),
penicillin–streptomycin solution (10,000 U/ml and 10 mg/ml,
respectively) and digitonin were SIGMA1 (Sigma-Aldrich
Chemie, Steinheim, Germany). Fetal Bovine Serum (FBS) was
Gibco1 (Invitrogen SA, Barcelona, Spain). The desalted and
full phosphorothioate form of G3139 ODN (50-TCT CCC
AGC GTG CGC CAT-30) and the mismatch control G4126
(50-TCT CCC AGC ATG TGC CAT-30) were purchased from
Microsynth (Balgach, Switzerland).
Cell Lines
The human variant and classic SCLC cell lines, respec-
tively SW2 and NCI-H69, were kindly provided by Drs. U.
Zangemeister-Wittke and R. Stahel (University Hospital of
Zurich, Switzerland). The human variant SCLC cell line NCI-
H82 SCLC cell line was purchased from the American Type
Culture Collection, whereas the K562 human leukemia cell
line was purchased from DMSZ GmbH. Cells were cultured
in RPMI 1640 supplemented with 10% (v/v) heat-inactivated
FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 10 mM
HEPES and 0.2% NaHCO3 at 378C in a humidified atmo-
sphere (90%), containing 5% CO2. Cells were maintained
within their exponential growth phase and periodically tested
for mycoplasma contamination with MycoAlert1 Myco-
plasma Detection kit (Cambrex Bio Science Verviers, Liege,
Belgium).
Selection of an Anti-Bcl-2 Monoclonal Antibody for
Flow Cytometry
In these experiments, three SCLC cell lines, known to
express different levels of Bcl-2 protein, as determined by Wes-
tern blot, were used: H82 (low), SW2 (intermediate) and H69
(high levels) (19). Cells were first fixed and permeabilized and
then submitted to three Bcl-2 immunostaining procedures,
aiming at assaying the Bcl-2 expression level by flow cytome-
try. With two of the immunostaining protocols tested, 106 tu-
mor cells in Dulbecco’s phosphate buffer saline (PBS) contain-
ing 1% BSA and 0.1% NaN3 were fixed and permeabilized
with the Fix and Perm kit (CaltagTM, Invitrogen, Barcelona,
Spain) according to the manufacturer procedure. Cells were
further incubated with 1 lg of fluorescein isothiocyanate
(FITC)-labeled mouse anti-human Bcl-2 monoclonal anti-
body, Bcl-2 mAb-FITC (IgG1, clone 100, Caltag, Invitrogen,
Spain), for 10 min. Alternatively, immunostaining was per-
formed by incubation with 1.3 lg of an anti-human Bcl-2
mouse monoclonal antibody (IgG1k, clone 124, Dako,
Glostrup, Denmark) for 10 min, followed by incubation with
2 lg of FITC-labeled secondary goat polyclonal anti-mouse
antibody (Dako, Glostrup, Denmark) for 20 min (indirect
staining). In these protocols, incubations with mAbs were per-
formed at room temperature in the dark. A third procedure
tested involved the fixation of 0.15 or 13106 tumor cells in
1% PFA in PBS containing 1% BSA and 0.1% NaN3 for 15
min at 48C. After washing with PBS containing 1% BSA and
0.1% NaN3, cells in 0.2 ml were incubated with 0.5 mg/ml dig-
itonin and 20 ll/106 cells of phycoerythrin (PE)-conjugated
mouse anti-human Bcl-2 mAb, Bcl-2 mAb-PE (IgG1k, clone
TECHNICAL NOTE
1166 Evaluation of Viability and Bcl-2 in SCLC
Bcl-2/100, BD PharmingenTM, BD Biosciences, Erembodegem,
Belgium) or the same volume of the correspondent PE-conju-
gated isotype control (iso-PE) (IgG1k, clone MOPC-21, BD
Pharmingen, BD Biosciences), for 10 min at 48C. After all im-
munostaining procedures, cells were washed once with 1 ml of
PBS containing 1% BSA and 0.1% NaN3, resuspended in PBS,
and at least 10,000 events acquired in a flow cytometer (BD
FACSCaliburTM, BD Biosciences, Erembodegem, Belgium).
The CellQuestTM Pro software (version 0.3, BD Biosciences,
Erembodegem, Belgium) was used in both acquisition and
data analysis. Plotted events were gated in a region in SSC/
FSC of predominantly viable cells and then the geometric
mean values of the relative fluorescence units (RFU) of the
FL1 or FL2 channels were considered, depending on the anti-
body label.
Treatment of Tumor Cells with Etoposide or Imatinib
SW2 cells were plated at a cell density of 0.5 3 106 cells/
ml in culture medium, in a 6-well plate, and treated with 0.8
lM etoposide (solution for IV injection from FARMA-APS
kindly donated by the University Hospital of Coimbra) in a
final volume of 1 ml, aiming at inducing cell death (including
apoptosis) (20). Medium and treatment renewal was per-
formed every 24 h. Untreated cells were equally manipulated
but resuspended, when appropriate, in fresh medium. At 72 h
after the first treatment, cells were collected and prepared for
cytometry analysis as described in the following section. As a
control for FITC-conjugated Annexin V solution staining
(Annexin V-FITC), K562 cells were included in the study. To
guarantee the presence of apoptotic cells, K562 cells under
treatment with imatinib (kindly donated by Novartis, Basel,
Switzerland) for induction of resistance, collected at a random
point after the beginning of imatinib treatments, were used.
Transfection of SW2 SCLC Cells with
Oligodeoxynucleotides
Cells were plated in 12-well plates (at 0.25 3 106 cells/
well) in 0.4 ml of culture medium composed only by RPMI
1640 without phenol red, and 25 mM HEPES. Oligofect-
amineTM (Invitrogen, Barcelona, Spain), diluted 5 times in
HEPES buffer saline, HBS (25 mM HEPES, 140 mM NaCl, pH
7.4), was added to ODN solutions, prepared in HBS, at a ratio
of 15 ll Oligofectamine/nmol ODN, and further incubated for
20 min at room temperature. Complexes (0.1 ml) were incu-
bated with tumor cells at 200 nM of ODN. RPMI 1640 (0.25
ml) supplemented with 30% FCS was added 4 h after the addi-
tion of complexes. Culture medium was added every day to
maintain cells in exponential growth phase (2-fold dilution),
and Bcl-2 and cell viability were evaluated at 72 h.
Concomitant Detection of Viability and Bcl-2 Protein
Level by Flow Cytometry
In the present study, the procedure for fixation and per-
meabilization and further Bcl-2 immunostaining of SCLC cells
(already stained with Annexin V-FITC and 7-AAD), was
adapted from Gao et al. (17). Tumor cells (0.15 3 106) in 0.1
ml of binding buffer (10 mM HEPES, 140 mM NaCl, 2 mM
CaCl2, pH 7.4) were incubated either with 7-AAD solution
(20 lg/ml), or with both 7-AAD (at the concentration just
mentioned) and 2 ll of Annexin V-FITC (Pharmingen, BD
Biosciences, Erembodegem, Belgium), for 15 min at 48C. Cells
were then washed once with binding buffer, and fixed in 1%
PFA in binding buffer for 20 min at 48C. Afterwards, cells
were washed with 1 ml of binding buffer containing 1% BSA,
0.1% NaN3 and 20 lg/ml AD, and incubated for 15 min in 0.2
ml of the previous washing buffer containing 0.5 mg/ml digi-
tonin and 8 ll of the Bcl-2 mAb-PE or of the correspondent
control (iso-PE). After washing once, with binding buffer con-
taining BSA and NaN3, cells were analyzed by flow cytometry.
About 40000 events were acquired and Annexin V-FITC, PE-
labeled mAbs and 7-AAD were measured in FL1, FL2, and FL3
channels, respectively. The settings and compensations were
adjusted for this assay.
RESULTS AND DISCUSSION
Characterization of the 7-AAD and Annexin V-FITC
Staining of SCLC Cells for Viability Determination
Fluorescently-labeled Annexin V has proven to be a use-
ful tool (usually in combination with propidium iodide or 7-
AAD) to distinguish viable from apoptotic and oncotic cells
(16,21). The usefulness of 7-AAD alone to stain non-viable
cells has also been reported. This marker can only penetrate
the plasma membrane when membrane integrity is compro-
mised, as occurs in the later stages of apoptosis or necrosis,
binding stoichiometrically to nuclear DNA. 7-AAD analysis
performed in combination with the FSC parameter further
distinguishes early apoptotic cells from viable and late apopto-
tic/necrotic cells. With this method, the early apoptotic sub-
population was described as the 7-AADlow1/smaller size
population (8).
Etoposide-treated SW2 cells, as well as untreated SW2
cells, and imatinib-treated K562 cells, were stained with 7-
AAD and Annexin V-FITC as described in Materials and
Methods section. Aiming at identifying, within SW2 SCLC
cells, the sub-population of viable cells as well as the subset of
cells in early stages of death induction, the combined analysis
of 7-AAD/Annexin V-FITC was compared to the combined
analysis FSC/7-AAD and FSC/Annexin V-FITC (Fig. 1). Such
analysis was performed after gating the events according to
their light scatter properties (SSC/FSC) to exclude part of
debris (not shown).
Double staining with 7-AAD and Annexin V-FITC is usu-
ally analyzed in the 7-AAD/Annexin V-FITC plot by drawing
quadrants (Figs. 1A–1C). Three sub-populations could be eas-
ily distinguished on the imatinib-treated K562 cells 7-AAD/
Annexin V-FITC plot (Fig. 1C), corresponding to three dis-
tinct centers of density falling within different quadrants. Late
apoptotic/necrotic cells stained more strongly with both 7-
AAD and Annexin V-FITC (7-AAD1/Annexin V-FITC1) fall-
ing in the upper-right quadrant, whereas viable cells (7-
AAD2/Annexin V-FITC2) and early apoptotic/oncotic cells
(7-AAD2/Annexin V1) were located in the lower-left and
lower-right quadrants, respectively. In contrast, with the SW2
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cells, although late apoptotic/necrotic cells were easily distin-
guished by staining more strongly with 7-AAD, viable cells
and early apoptotic/oncotic cells sub-populations could not be
easily delimited from each other (Figs. 1A and 1B). As com-
pared to imatinib-treated K562 cells (Fig. 1C), viable SW2
cells displayed a higher basal intensity of Annexin V-FITC sig-
nal. This, together with dispersion in signal from doublets or
higher cell number events, makes positive and negative popu-
lations for Annexin V-FITC signal partially overlap and there-
fore difficult to distinguish, introducing uncertainty in the
quadrants positioning and subsequent quantification of
events. The same Annexin V-FITC and 7-AAD staining pat-
terns were observed with untreated SCLC H82 and H69 cells
(not shown), suggesting that the described features are gener-
ally applicable to SCLC cell lines, and are not exclusive of the
SW2 cell line.
Figure 1. Assessment of viability of SCLC and leukemia cells by multiparametric flow cytometry. Untreated and etoposide-treated SW2
SCLC cells and imatinib-treated K562 leukemia cells were stained with 7-AAD and Annexin V-FITC. Annexin V-FITC and 7-AAD fluorescence
were plotted in contour plots in combination with each other (A—C) and with the FSC parameter (D—I). Geometric regions labeled from
R2 to R6 delimit regions containing distinct sub-populations of events, based on the distinct properties of the parameters under analysis.
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Given the previous reported limitations, the analysis of the
7-AAD fluorescence in combination with FSC was carried out
(8). The lines defining the quadrants in Figures 1A–1C, were
positioned more accurately after gating FSC/7-AAD and FSC/
Annexin-V plots. In the FSC/7-AAD contour plot (Figs. 1D–
1F), three regions corresponding to distinct cellular sub-popu-
lations can be delimited: 7-AAD2 and normal sized events
(R2), 7-AADlow 1 and normal to small sized events (R3), and
7-AAD1 and normal to small sized events (R4). The events
within R2 and R4 correspond to viable cells and late apoptotic/
necrotic cells, respectively. The nature of the events within R3 is
less clear, although it might correspond to early apoptotic or
oncotic cells (8), as well as cell debris. Unstained cells already
present events within this region (not shown), indicating that
at least a fraction of the events within the R3 region exhibit not
true 7-AADlow1 signal but rather higher auto-fluorescence.
The FSC parameter revealed to be useful in viability discrimina-
tion not only when used together with 7-AAD fluorescence but
also when conjugated with the Annexin V-FITC signal. Com-
bining the FSC information with the Annexin V-FITC signal
(Figs. 1G and 1H), the region of viable cells (R5) is better discri-
minated from dying or late apoptotic/necrotic cells (R6) than
in the 7-AAD/Annexin V-FITC plots (Figs. 1A and 1B).
At this stage, it was therefore important to compare 7-
AAD and Annexin V-FITC (in conjunction with the FSC
parameter) in terms of the percentage of cells in different sub-
populations. The percentage of viable cells determined with
7-AAD (R2) (Figs. 1D–1F) or Annexin V-FITC (R5) (Figs. 1G–
1I), was equivalent in all three groups of cells tested (Fig. 2A),
indicating that both procedures are suitable to determine quan-
titatively the viable cell population. In addition, it might be im-
portant to assess the cells in early phases of death induction,
which, as previously referred for SW2 cells, is not determined
with precision through the establishment of quadrants in the 7-
AAD/Annexin V-FITC plot (Figs. 1A and 1B). This quantifica-
tion can be carried out by subtracting the number of events
within R4 region on the FSC/7-AAD plot (corresponding to
late apoptotic/necrotic cells) to the number of events within the
R6 region on the FSC/Annexin V-FITC plot (corresponding to
early and late apoptotic/necrotic cells), Figure 1. Alternatively,
determination can be based on the R3 region in the FSC/7-
AAD plot (Fig. 1). The percentage of events determined by each
procedure revealed to be similar (Fig. 2B).
Despite the previous finding, the methods do not discri-
minate exactly overlapping populations of viable cells and cells
in a phase of death induction. This was illustrated for etopo-
side-treated SW2 cells in Figures 2C and 2D, and was quantified
for all three conditions (Figs. 2E and 2F). In an FSC/Annexin
V-FITC plot of etoposide-treated cells gated in R2, the percent-
age of total events within R6 (10%) represents either the false
positive non-viable cells found by Annexin V-FITC or the false
negative non-viable cells determined in the FSC/7-AAD analy-
sis (Fig. 2C). This type of discrepancy was negligible (2%) in
untreated-SW2 and K562 cells (Fig. 2E). Furthermore, in an
FSC/Annexin V-FITC plot gated in R3, the percentage of cells
within R5 represents the false negative non-viable events found
by Annexin V-FITC or the false positive events determined in
the FSC/7-AAD analysis (Fig. 2D). This discrepancy was mini-
mal (1–2%) in untreated and etoposide-treated SW2 cells and
in the order of 6% in K562 leukemia cells (Fig. 2F). The use of
complementary methods like evaluation of caspase activation
and/or the terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling (TUNEL) assay are, therefore, required
to warrant a clear definition of apoptosis induction, if this is a
concern. Nevertheless, the percentages determined show that
the putative false positives or false negatives have little impact
in overall viability determination.
As the final goal is to analyze Bcl-2 levels in correlation
with viability, the compatibility of both Annexin V-FITC and
7-AAD with a PE-labeled antibody is, as well, of interest for
the discussion of viability analysis methods, and will be
addressed in the last section of Results and Discussion.
Selection of an Anti-Human Bcl-2 Monoclonal
Antibody to Evaluate Bcl-2 Levels and Heterogeneity
of Protein Expression in SCLC Cells
To establish a sensitive procedure to detect Bcl-2 in
SCLC, with good discrimination between different Bcl-2 levels,
aiming at providing a correlation between fluorescence signal
and Bcl-2 levels, three different procedures were evaluated.
H82, SW2, and H69 SCLC cell lines, expressing low, interme-
diate and high Bcl-2 levels, respectively, were used (19). The
Bcl-2 mAb-FITC did not discriminate between different Bcl-2
levels, namely within the range of intermediate and high levels
of Bcl-2 (Fig. 3). In contrast, the indirect staining procedure
(unlabeled anti-Bcl-2 plus FITC-labeled secondary Ab) and
the direct staining with Bcl-2 mAb-PE provided a good discri-
mination (positive correlation between fluorescent signal and
Bcl-2 levels). The correspondent unspecific iso-PE signal was
very low and equivalent for the three cell lines, demonstrating
the specificity of the signal (Fig. 3). A careful antibody selec-
tion is crucial for a correct evaluation of any gene silencing
strategy involving the downregulation of Bcl-2 in SCLC and
likely in any type of tumor. For example, the downregulation
of Bcl-2 from a high level to an intermediate level of expres-
sion (Fig. 3) would not be detected with the Bcl-2 mAb-FITC,
leading to misinterpretation of results. The simplicity, sensitiv-
ity and specificity of the use of the Bcl-2 mAb-PE led us to
select this mAb for further studies.
The evaluation of the Bcl-2 levels by flow cytometry evalu-
ates not only the mean protein levels, as shown in Figure 3 and
as provided by other quantification methods like Western blot
and enzyme-linked immunosorbent assays, but, in addition, it
also gives information about the heterogeneity of the protein
expression. It was possible to identify in Bcl-2-low expressing
H82 cells a small (around 2%), but reproducible, percentage of
viable cells with high Bcl-2 expression. The staining with the
isotype control mAb does not detect any events within this
region proving its specificity (data not shown). This is the type
of information that would not be detected by Western blot,
emphasizing the advantage of flow cytometry in detecting in-
tracellular proteins in cases of heterogeneous protein expres-
sion, as a result, for example, of a incomplete cell transfection
with a gene silencing molecule (4).
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Concomitant Measurement of Cell Viability and Bcl-2
Protein Level by Flow Cytometry
The simultaneous evaluation of cell viability and Bcl-2
protein level requires the establishment of procedures that
guarantee an accurate correlation. Bcl-2 being an intracellular
protein, its immunodetection requires cell fixation and perme-
abilization. The selection among the several available methods
to fix and permeabilize cells should consider their impact on
cell viability assessment. In the present study, cells fixed with
1% PFA and permeabilized with digitonin had the same
Annexin V-FITC and 7-AAD staining patterns and FCS distri-
bution than cells acquired in flow cytometry immediately after
Figure 2. Comparison of Annexin V-FITC and 7-AAD methods analyzed each one in combination with the FSC parameter. In all three
groups of cells studied, the percentage of viability (A) and the percentage of events in early phases of death induction (B) were quantified.
Events were also displayed in FSC/Annexin V-FITC contour plots gated in the R2 or R3 regions of FSC/7-AAD plots, as exemplified for eto-
poside-treated SW2 cells (C and D, respectively). The percentage of total events gated in R2 or R3 falling into each of the gated regions of
the Annexin V-FITC plot is presented for all three studied conditions (E and F). This percentage of events corresponds to the fraction of
false positives or false negatives with each stain.
TECHNICAL NOTE
1170 Evaluation of Viability and Bcl-2 in SCLC
staining (not shown). Therefore, the selected fixation and per-
meabilization procedures revealed to be compatible with the
selected markers of viability, without compromising the mor-
phology of the cells, namely in respect to size.
The results presented in Figure 4, A and B, confirm the
applicability of the method here presented, aiming at the simul-
taneous assessment of SCLC viability and Bcl-2 protein.
Untreated SW2 cells were stained with 7-AAD and Bcl-2 mAb-
PE, and viability regions (R2, R3, and R4) selected as previously
described. The treatment with the sequence-specific G3139
ODN induces a reduction of the mean Bcl-2 signal in both viable
and dead cells sub-populations (30 and 41 RFU, respectively,
Fig. 4A) as compared with the treatment with G4126 ODN (49
and 65 RFU, respectively, Fig. 4B). The percentage of viable and
dead cells was not significantly different among the tested treat-
ments. Moreover, it was possible to observe that Bcl-2 silencing
was heterogeneous, as evidenced by the broader Bcl-2 signal fre-
quency histograms of the G3139 ODN-treated SW2 (viable)
cells (Fig. 4C, thick black line) as compared with the histogram
of untreated cells (Fig. 4C, dark gray histogram). In addition,
the histogram subtraction of the untreated SW2 (viable) cells to
the G3139-treated SW2 (viable) cells turned possible the deter-
mination of the percentage of Bcl-2-silenced cells as well as their
mean Bcl-2 signal (Fig. 4C, light gray histogram).
To our knowledge, the present results demonstrate for the
first time that both 7-AAD and Annexin V-FITC stains are
compatible with Bcl-2 intracellular protein immunostaining
using a PE-labeled antibody in SCLC cells. Moreover, when
analyzed in combination with the FSC parameter, this
approach provides a helpful and convenient method for the
simultaneous analysis of Bcl-2 level and cell viability in SCLC
cells. Surprisingly, results demonstrated that Annexin V-FITC
staining is less sensitive than 7-AAD alone in SCLC cells, as
well as than Annexin V-FITC staining in other cell lines (like
leukemia cells). It is therefore clear that 7-AAD is the best
choice to determine viability in SCLC cells. Furthermore, the
FSC/7-AAD method will allow the simultaneous study of
Figure 3. Correlation between fluorescence signal and Bcl-2 pro-
tein of levels in SCLC cell lines. Several SCLC cell lines expressing
different levels of Bcl-2 protein were submitted to three immuno-
staining procedures, corresponding to the incubation with differ-
ent monoclonal antibodies. The immunodetection comparison
among the mAb tested was based on the geometric mean values
of fluorescence.
Figure 4. Simultaneous evaluation of viability and Bcl-2 protein in
SW2 SCLC cells. Regions were created as in Figure 1D and then
the events were plotted in 7-AAD/Bcl-2-PE dot plots representative
of cells treated with G3139 ODN (A) or G4126 ODN (B). Events cor-
responding to R2, R3, or R4 regions are in black, light gray, or in
dark gray, respectively. Next to R2 or R4 regions, it is indicated
the percentage of gated events and the geometric mean of Bcl-2
signal intensity (RFU) in the correspondent region. The corre-
spondent overlayed frequency histograms of the viable popula-
tions of different treatment conditions are presented.
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other parameters, besides viability and Bcl-2 expression, even
in the simplest three-color flow cytometer. We have recently
observed the usefulness of this procedure to the evaluation of
Bcl-2 silencing in breast cancer cell lines.
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